Carta Healthcare Strengthens Oncology Research Capabilities
Carta Healthcare is taking significant strides in improving healthcare by acquiring Realyze Intelligence, a sophisticated AI platform focused on oncology. This acquisition enhances Carta Healthcare's ability to harness clinical data effectively, optimizing the recruitment of patients for clinical trials. The technology deployed by Realyze Intelligence can drastically reduce the time and cost associated with identifying suitable candidates for research studies.
Transforming Patient Recruitment with AI
Realyze Intelligence stands out by employing clinician-trained artificial intelligence to sift through electronic health records (EHRs), accelerating the process of matching patients with clinical trials. Traditionally, this vital process takes hours or even days, but with Realyze, it is reduced to mere seconds. This modern approach not only increases efficiency but also expands the potential for patient participation in groundbreaking research.
Meeting the Needs of Cancer Research
With a concentration on oncology, the Realyze platform delivers rapid analyses of both structured and unstructured data within EHRs. It enables healthcare providers to pinpoint ideal candidates for clinical trials quickly. Renowned cancer centers are already using this technology to enhance their research capabilities, demonstrating a commitment to advancing patient care.
Capitalizing on Data for Better Outcomes
The integration of Realyze Intelligence into Carta Healthcare's offerings signifies an essential evolution in how clinical trials and cancer registries operate. The platform’s capabilities extend beyond just patient matching; it also helps streamline data abstraction processes, thereby significantly reducing labor costs and resource requirements for healthcare professionals.
Driving Change in Clinical Trials
As highlighted by Brent Dover, CEO of Carta Healthcare, the value of data in healthcare cannot be overstated. Every data point holds the potential to inform better care practices and ultimately improve patient outcomes. The acquisition allows for a synergistic relationship, maximizing insights drawn from clinical data through the combined power of AI and human expertise.
The Current Landscape of Cancer Care
With cancer emerging as the leading cause of death globally, the urgency for innovative solutions to enhance patient outcomes is paramount. Traditional methods of finding eligible clinical trial participants are steeped in challenges, as many criteria reside in unstructured notes, making extraction burdensome. Carta Healthcare addresses these challenges directly by utilizing enhanced AI capabilities to facilitate the trial process.
Benefits to Healthcare Systems and Pharmaceutical Companies
The integration of Realyze Intelligence will fortify healthcare systems and pharmaceutical companies in their quest to identify and enroll patients in clinical trials cost-effectively and efficiently. As Aaron Brauser, founder and CEO of Realyze Intelligence, emphasizes, the need for timely and high-quality data has never been more critical for enhancing clinical trial matching and improving research outcomes.
About Carta Healthcare
At its core, Carta Healthcare is dedicated to revolutionizing data abstraction methods. By leveraging the synergy of artificial intelligence alongside skilled data professionals, the company aims to streamline processes, making them less time-consuming and more efficient. The ultimate goal is to bring about a transformation in healthcare data management that leads to better patient outcomes.
About Realyze Intelligence
This innovative company, part of UPMC Enterprises, employs AI to quickly analyze data and identify patients suitable for open clinical trials. By utilizing advanced technology, they aim to expedite the matching process significantly, reducing the time typically required for such procedures.
Frequently Asked Questions
What is Carta Healthcare's recent acquisition?
Carta Healthcare has acquired Realyze Intelligence, enhancing its AI capabilities for oncology research.
How does Realyze Intelligence improve patient recruitment?
By utilizing AI to process electronic health records, it matches patients to clinical trials in seconds.
What are the benefits of AI in oncology research?
AI helps speed up data analysis and patient matching, making research more efficient and cost-effective.
Who can benefit from Carta Healthcare's solutions?
Healthcare systems, pharmaceutical companies, and oncology research institutions can all benefit from enhanced patient recruitment strategies.
What is the mission of Carta Healthcare?
Carta Healthcare aims to transform healthcare through high-quality data management and efficient processes that improve patient outcomes.
